Trials / Completed
CompletedNCT01418937
Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine (GSK-580299) in Healthy Female Control Subjects From the GSK HPV-023 Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 164 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 26 Years
- Healthy volunteers
- Accepted
Summary
This phase IIIb study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in the HPV-023 (NCT00518336) study and received a placebo in the HPV-001 (NCT00689741) study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CervarixTM (GSK580299) | Three intramuscular injections |
Timeline
- Start date
- 2012-05-29
- Primary completion
- 2015-01-09
- Completion
- 2015-01-09
- First posted
- 2011-08-17
- Last updated
- 2018-07-12
- Results posted
- 2015-08-21
Locations
5 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT01418937. Inclusion in this directory is not an endorsement.